The Journal of Experimental Medicine
StemCell Technologies
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online 24 November 2003 doi:10.1084/jem.20031030
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dhodapkar, M. V.
Right arrow Articles by Geller, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dhodapkar, M. V.
Right arrow Articles by Geller, M. D.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© Rockefeller University Press, 0022-1007/2003/12/1753 $5.00
The Journal of Experimental Medicine, Volume 198, Number 11, 1753-1757

Brief Definitive Report

 Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy

Madhav V. Dhodapkar1,2, Joseph Krasovsky1, Keren Osman1 and Matthew D. Geller1

1 Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University
2 Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021

Address correspondence to Madhav V. Dhodapkar, Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, 1230 York Ave., New York, NY 10021. Phone: (212) 327-8114; Fax: (212) 327-7119; email: dhodapm{at}mail.rockefeller.edu

Most approaches targeting the immune system against tumors have focused on patients with established tumors. However, whether the immune system can recognize preneoplastic stages of human cancer is not known. Here we show that patients with preneoplastic gammopathy mount a vigorous T cell response to autologous premalignant cells. This preneoplasia-specific CD4+ and CD8+ T cell response is detected in freshly isolated T cells from the BM. T cells from myeloma marrow lack this tumor-specific rapid effector function. These data provide direct evidence for tumor specific immune recognition in human preneoplasia and suggest a possible role for the immune system in influencing the early growth of transformed cells, long before the development of clinical cancer.

Key Words: myeloma • vaccine • dendritic cells • prevention • gammopathy


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS